Insulet | PODD - Gross Profit On Sales


Insulet reported $562.6M in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Abbott USD 6.65B 787M Jun/2026
Align Technology USD 757.43M 20.84M Jun/2026
AtriCure USD 109.31M 3.97M Mar/2026
Baxter International USD 1.14B 251M Jun/2026
Becton, Dickinson and Co. USD 2.32B 161M Jun/2026
Boston Scientific USD 3.82B 210M Jun/2026
Cardinal Health USD 2.5B 101M Mar/2026
Cooper Companies USD 735.4M 40.2M Mar/2026
Dexcom USD 750.3M 42.4M Mar/2026
Edwards Lifesciences USD 1.35B 62.6M Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Globus Medical USD 548.17M 51.91M Jun/2026
ICU Medical USD 235.05M 28.83M Jun/2026
Inogen USD 41.34M 1.39M Sep/2024
Insulet USD 562.6M 21.8M Jun/2026
Integra LifeSciences USD 215.97M 2.77M Jun/2026
J&J USD 18.55B 1.31B Jun/2026
Medtronic USD 6.01B 595M Mar/2026
Merit Medical Systems USD 215.17M 30.37M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Solventum Corp USD 1.29B 189M Jun/2026
Stryker USD 4.5B 688M Jun/2026
Tandem Diabetes Care USD 144.78M 7.99M Jun/2026
Teleflex USD 331.71M 24.28M Jun/2026
West Pharmaceutical Services USD 296.4M 7.5M Mar/2026
Zimmer Biomet Holdings USD 1.36B 149.4M Jun/2026